180 results on '"Jeanpierre, Emmanuelle"'
Search Results
2. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
3. The role of tranexamic acid in the management of postpartum haemorrhage
4. Tranexamic acid dose–response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study
5. Heparin Dosing Regimen Optimization in Veno-Arterial Extracorporeal Membrane Oxygenation: A Pharmacokinetic Analysis
6. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
7. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B
8. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
9. Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
10. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence
11. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma
12. ABO Blood Groups in Systemic Sclerosis: Distribution and Association with This Disease’s Characteristics
13. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
14. Tranexamic acid dose–response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study
15. von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment
16. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial
17. Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial
18. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider
19. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
20. A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology
21. Aortic endothelial cells response to pulsatile vs. continuous flow at high shear stress
22. Derivation and Validation of a Predictive Score for Respiratory Failure Worsening Leading to Secondary Intubation in COVID-19: The CERES Score
23. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor–thrombin pathway and potential role through osteopontin alteration
24. Is low dose Tranexamic acid less effective than a standard dose at reducing blood loss and inhibiting hyperfibrinolysis in hemorrhagic caesarean section? Multicenter double–blind placebo-controlled dose-ranging (TRACES) trial.
25. Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits
26. Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques
27. ABO Blood Groups in Systemic Sclerosis: Distribution and Association with This Disease's Characteristics.
28. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: Evidence for a corrective effect of statins
29. The homozygous variant p.Gln1311* in exon 28 of VWF is associated with the development of alloantibodies in 3 unrelated patients with type 3 VWD
30. Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature
31. Inaugural fibrinolysis in a paradoxal Amniotic Fluid Embolism: An illustrated case-report and review
32. Impact of aPTT reagents on measurement of a PEGylated recombinant FVIII (Adynovi®/Adynovate®): A French multicentric field assay study.
33. von Willebrand Factor and Management of Heart Valve Disease JACC Review Topic of the Week
34. Factor VIII assays in treated hemophilia A patients
35. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease
36. Risk of Pulmonary Embolism More Than 6 Weeks After Surgery Among Cancer-Free Middle-aged Patients
37. Factor VIII assays in treated hemophilia A patients
38. Factor IX assays in treated hemophilia B patients
39. Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19.
40. Additional file 1: of TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial
41. Additional file 2: of TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial
42. Additional file 1: of Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial
43. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
44. Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
45. Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates.
46. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
47. Multicenter Pharmacokinetic Evaluation of rFVIII-Fc (Elocta) in a Real Life and Comparison with Non-Extended Half-Life FVIII Concentrates
48. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
49. Referee report. For: Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): protocol and statistical analysis plan for a randomized controlled trial [version 1; referees: 3 approved]
50. Referee report. For: Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study [version 1; referees: 1 approved]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.